Takeda stops development of Fasiglifam, a novel type-2 diabetes drug

The candidate drug, TAK-875, was in the global phase-III development stage. Development was discontinued due to potential side-effects. As the drug is based on a novel mechanism of action and was positioned as a major source of future revenue, the announcement will...

JST and Israel’s MOST start cooperation program

The initial projects will focus on biomarker for amyotrophic lateral sclerosis (ALS), the molecular basis of neurodevelopmental disorders in schizophrenia and research on the molecular pathogenesis and neural abnormalities in old age depression JST news release,...